European Study of POBA Versus Cotavance(R) Paclitaxel Coated Balloon for the Treatment of Infrapopliteal Lesions in Critical Limb Ischemia (EURO CANAL)
Phase 2
Terminated
- Conditions
- PADInfrapopliteal Lesions
- Interventions
- Device: Cotavance Paclitaxel Coated BalloonDevice: Standard balloon angioplasty
- Registration Number
- NCT01260870
- Lead Sponsor
- Bayer
- Brief Summary
To evaluate the procedural safety and to identify and characterize therapeutic and functional endpoint assessments in subjects with documented critical limb ischemia who received treatment with the Cotavance Paclitaxel-Coated Balloon vs. those who received POBA only.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- All
- Target Recruitment
- 44
Inclusion Criteria
- Subjects with CLI
Read More
Exclusion Criteria
- Participation in another research trial
- Medical conditions the study doctor will assess
Read More
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Cotavance Cotavance Paclitaxel Coated Balloon - Standard balloon angioplasty Standard balloon angioplasty POBA
- Primary Outcome Measures
Name Time Method Evaluate procedural safety 30 days
- Secondary Outcome Measures
Name Time Method Identify and characterize therapeutic and functional endpoint assessments 5 years
Trial Locations
- Locations (4)
Medical University
🇦🇹Graz, Austria
AZ St.-Blasius Hospital
🇧🇪Dendermonde, Belgium
University Hospital
🇨ðŸ‡Zurich, Switzerland
St. George's Hospital
🇬🇧London, United Kingdom